- CME/CE Activities
- Nonpharmacological Treatment of Depression
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201000006G from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Applying AHRQ's Comparative Effectiveness Research in Nonpharmacological Treatment of Depression and Discussion in Military Settings
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Disclosures
- Activity
- Post-Test & Evaluation
To Receive a Certificate for This Activity:
- 1. Read the Program Overview on this page.
- 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
- 3. Access the Activity in full.
- 4. Complete the Post-Test & Evaluation.
- 5. A printable certificate will be available immediately following the activity.
Program Overview
Activity Description
Depression transcends patient populations with causative factors that can include serious illness, substance abuse, life-threatening events, genetics, conflict, and other factors. Treatment-resistant depression also crosses patient populations in both military and civilian settings and can occur in times of war and peace, during recessions, and in periods of economic growth. Are nonpharmacological interventions effective and safe in reducing symptoms of depression in patients with treatment-resistant depression? How do nonpharmacological approaches compare with standard medical treatments? This innovative video program pairs a psychologist and a physician representing military and civilian patient populations to address these questions based on the key findings from the Agency for Healthcare Research and Quality's (AHRQ)comparative effectiveness review in treatment-resistant depression.Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Compare the effectiveness of these interventions against each other, as well as against standard medications, for treating acute-phase symptoms of depression in both military and civilian populations
- Evaluate comparisons between these interventions with regard to safety, adverse events, and adherence
- Discuss the AHRQ review findings to managing TRD across military and civilian settings, with special emphasis on guiding patient-centered shared and informed decision making
Target Audience
This CME activity is designed to meet the educational needs of physicians, psychologists, nurse practitioners, physician assistants, nurses, case managers and health education specialists.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online (Hardware/Software Requirements: Broadband & Flash Player or HTML5 browser)
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
November 30, 2011 through November 30, 2013. Original release date: November 30, 2011
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Speaker
Harold R Veits, MD
State of Alabama Medical Consultant
Disability Determination Services
Adjunct Faculty
Department of Psychiatry
University of South Alabama
Past Staff Psychiatrist
Alabama Psychiatric Services
Mobile, AL
Speaker
M David Rudd, PhD, ABPP
Dean, College of Social & Behavioral Science
University of Utah
Scientific Director
National Center for Veterans Studies
University of Utah
Salt Lake City, UT
Planner
Carolyn LePage, PhD, ARNP
Assistant Professor
Barry University School of Nursing
Miami Shores, FL
Planner
Heidi Wynn Maloni, PhD, ANP-BC
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC
Planner
Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office
Peer Reviewer
David V Sheehan, MD, MBA
Professor of Psychiatry
Director of Depression and Anxiety Disorders Research Institute
University of South Florida
College of Medicine
Tampa, FL
Peer Reviewer
Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA
Peer Reviewer
Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Ft Lauderdale, FL
Accreditation/Credit Designation
Physician Credit Designation Statement
PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistant Accreditation Statement
AAPA accepts AMA Category 1 CME Credit™ for the PRA from organizations accredited by ACCME.
Nurse Practitioner Accreditation Statement
PRIME Education, Inc. (PRIME®) is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER18.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Nurse Accreditation Statement
PRIME Education, Inc. (PRIME®) is an Approved Provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
PRIME® designates this activity for 1.0 contact hour.
Case Manager Accreditation Statement
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.
Certified Health Education Specialist Accreditation Statement
Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.
This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.
CHES Provider Number: SSP3769
Faculty Disclosures
| Faculty Name | Advisory Board | Consultant | Grants / Research | Salary / Contractual | Supported Promotional Education | Stock / Shareholder | Other Financial Support |
|---|---|---|---|---|---|---|---|
| Harold R Veits, MD Speaker |
None | None | None | None | None | Pfizer | None |
| M David Rudd, PhD, ABPP Speaker |
None | None | None | None | None | None | None |
| Carolyn LePage, PhD, ARNP Planner |
None | None | None | Barry University | None | None | None |
| Heidi Wynn Maloni, PhD, ANP-BC Planner |
sanofi-aventis | None | None | None | None | None | None |
| Wanda F Carter, MPH, CHES Planner |
none | None | None | None | None | None | None |
| David V Sheehan, MD, MBA Reviewer |
Labopharm/Angelini, Otsuka, Lundbeck | Labopharm/Angelini, GlaxoSmithKline, Eli Lilly, Pfizer, Otsuka, Lundbeck, Roche, Medical Outcomes Systems | AstraZeneca, Dainippon Sumitomo/Sunovion | Labopharm/Angelini, GlaxoSmithKline, Eli Lilly, Pfizer, AstraZeneca, Otsuka, Roche | Labopharm/Angelini, GlaxoSmithKline, Eli Lilly, Hikma, MAPI | Medical Outcomes Systems | None |
| Joyce M Knestrick, PhD, CRNP, FAANP Reviewer |
none | None | None | None | None | None | None |
| Kathleen A Jarvis, MS, RN, CCM Reviewer |
none | None | None | None | None | None | None |
| Chris R Prostko, PhD Scientific Program Director | None | None | None | PRIME® | None | None | None |
| Lynn Goldenberg, RN, BSN Director of Accreditation & Compliance | None | None | None | PRIME® | None | None | None |
Disclosure Policy
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
Aconflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME complete disclosures which are related to their role in the educational activity.
Accessibility
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.


